|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
Moderna’s combination Covid, flu vaccine is more effective than existing shots in late-stage trial
Moderna’s messenger RNA combination shot, called mRNA-1083, is made up of both the company’s vaccine candidate for seasonal influenza and a newer, “next-generation” version of its Covid shot. Both of those experimental vaccines – mRNA-1010 and mRNA-1283 – have shown positive results in separate phase three trials.
The ongoing late-stage trial on mRNA-1083 examined the combination shot in 8,000 patients.
The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna’s currently licensed Covid shot, Spikevax, in one group of patients ages 65 and above. The trial also compared Moderna’s combination jab with a standard flu shot called Fluarix and Spikevax in another group of participants between the ages of 50 and 64.
In both age groups, a single dose of Moderna’s combination vaccine produced “statistically significantly higher” immune responses against three strains of influenza and the Covid omicron variant XBB.1.5.
Moderna said the safety of the combination shot, along with how well patients could tolerate it, was acceptable. The most common side effects were injection site pain, fatigue, muscle pain and headache. The majority of those effects were mild to moderate in severity. |
|
|
|
| номер сообщения: 49-54-43762 |
|
|
| |
|
|
|
|
|
|
|
| Copyright chesspro.ru 2004-2024 гг. |
|
|
|
